EP
REGN icon

Elkfork Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Elkfork Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.84M Sell
6,622
-88
-1% -$26K 0.04% 284
2019
Q2 		$2.1M Sell
6,710
-5,544
-45% -$1.85M 0.05% 272
2019
Q1 		$5.03M Buy
12,254
+8,250
+206% +$3.4M 0.13% 155
2018
Q4 		$1.5M Buy
4,004
+1,078
+37% +$395K 0.04% 292
2018
Q3 		$1.18M Buy
2,926
+660
+29% +$251K 0.03% 344
2018
Q2 		$782K Buy
2,266
+44
+2% +$13.8K 0.02% 403
2018
Q1 		$765K Sell
2,222
-374
-14% -$130K 0.02% 408
2017
Q4 		$976K Buy
2,596
+1,210
+87% +$490K 0.03% 371
2017
Q3 		$620K Sell
1,386
-66
-5% -$31.4K 0.02% 438
2017
Q2 		$713K Sell
1,452
-154
-10% -$67.4K 0.02% 396
2017
Q1 		$622K Sell
1,606
-22
-1% -$8.15K 0.02% 402
2016
Q4 		$597K Buy
+1,628
New +$619K 0.02% 382

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Elkfork Partners's REGN Position: Q3 2019 in Review

Elkfork Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 1.3% in Q3 2019, selling an estimated $26K and leaving 6,622 shares worth $1.84M. The position accounts for 0.04% of the portfolio, ranked #284.

Elkfork Partners first reported a position in REGN in Q4 2016 and has held it in 12 quarters since. The position peaked at $5.03M in Q1 2019. 633 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

  • Elkfork Partners held 6,622 shares of Regeneron Pharmaceuticals worth $1.84M as of Q3 2019.
  • Elkfork Partners sold 88 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $26K.
  • Regeneron Pharmaceuticals made up 0.04% of Elkfork Partners's portfolio in Q3 2019, its #284 holding.
  • Elkfork Partners first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
  • Elkfork Partners's Regeneron Pharmaceuticals position peaked at $5.03M in Q1 2019.
  • 633 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.